Purpose: To evaluate the use of a chitosan-based hemostatic dressing (CBHD) (ChitoFlex, HemCon Medical Technologies Inc., Portland, OR, U.S.A.) as an effective adjunct for hemostasis in dacryocystorhinostomy surgery and compare its effectiveness to collagen absorbable hemostat (CAH) (Insat, Johnson & Johnson Gateway, New Brunswick, NJ, U.S.A.).
Methods: Retrospective, comparative case series. Thirty-five external or endoscopic dacryocystorhinostomy (DCR) and conjuctival dacryocystorhinostomy (CDCR) procedures were performed on 26 patients using the CBHD from May through October 2007. Thirty-five external or endoscopic DCR or CDCR procedures were performed on 27 patients using CAH from February through May 2007. Collection of patient data in the group treated with CBHD included the types of cases performed, surgical outcome, complications, adverse reactions, and telephone follow-up survey of symptomatic results. Collection of patient data in the group treated with CAH primarily focused on the types of cases performed and postoperative bleeding. The main outcome measures were postoperative bleeding and need for anterior nasal packing.
Results: Postoperative bleeding occurred in 2 cases in the group treated with CBHD and in 12 cases in the CAH group.
Conclusions: The study demonstrates the effectiveness and safety of CBHD as a hemostatic agent in DCR and CDCR and as a promising alternative to CAH.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/IOP.0b013e3181b30108 | DOI Listing |
Curr Opin Infect Dis
January 2025
Department of Medicine, Clínica Rotger Quironsalud, Palma de Mallorca, Spain.
Purpose Of Review: Optimal duration of therapy in SSTIs - a heterogeneous group of infections - remains unknown. The advances in knowledge of antibiotic duration of treatment in selected SSTIs that can impact clinical practice and published in the last 18 months are reviewed.
Recent Findings: Recent evidence indicates that few patients receive guideline concordant empiric antibiotics and appropriate duration in the United States, although this likely can be extrapolated to other countries.
Clin J Pain
January 2025
Department of Anesthesiology and Perioperative Medicine, University of South Florida, Morsani College of Medicine, Tampa, Florida, USA.
Objectives: Complex regional pain syndrome remains a challenging condition characterized by severe, persistent pain and a variety of inflammatory and trophic symptoms. This study aimed to analyze the current literature to evaluate hyperbaric oxygen therapy (HBOT)'s efficacy in treating complex regional pain syndrome (CRPS), focusing on both sympathetically-maintained pain (SMP) and sympathetically-independent pain (SIP) subtypes.
Methods: A comprehensive literature search was conducted in PubMed Clinical Queries using the MeSH term "Complex Regional Pain Syndromes" OR the keyword "CRPS" AND "Hyperbaric Oxygen Therapy" OR the keyword "HBOT".
Sci Prog
January 2025
Department of Obstetrics and Gynecology, Hebei Medical University Third Hospital, Shijiazhuang, China.
Objective: Endometrial cancer (EC) is a malignant tumor with various histological subtypes and molecular phenotypes. The evaluation of drug resistance is important for cancer treatment. Progesterone resistance is the major challenge in EC.
View Article and Find Full Text PDFClin Infect Dis
January 2025
Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Comprehensive Cancer Center, Stockholm, Sweden.
Herpes simplex virus (HSV) infection is one of the most prevalent viral infections worldwide. In general, host immunity is sufficient to clear viral shedding and recurrences, although it is insufficient to prevent subsequent virologic reactivations. In immunocompromised patients, prolonged and difficult-to-treat HSV infections may develop.
View Article and Find Full Text PDFClin Appl Thromb Hemost
January 2025
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA.
Limited available evidence comparing DOACs with warfarin suggests efficacy and safety of DOACs for CVT. We aimed to evaluate whether a specific DOAC is preferred for the treatment of CVT. This retrospective cohort study included adult patients with CVTs between September 2018 and September 2022 treated with a DOAC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!